All In Biotech

Drug Trial Radar · NCT05896670

Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease

A Multi-center, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Licaminlimab for the Treatment of Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 122 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

122

Actual

Start

Nov 29, 2023

Primary completion

Mar 27, 2024

Study completion Mar 27, 2024

Sponsor

Lead sponsor
OculisIndustry
Sponsor type
Industry
Collaborators
ORA, Inc.
First posted
Jun 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating signs of dry eye disease.

Conditions

  • Dry Eye Disease

Interventions

  • licaminlimabDrug

    ophthalmic solution 60 mg/mL Subjects will be randomized to receive licaminlimab eye drops three times daily (TID) for 6 weeks.

  • vehicle of OCS-02Other

    inert ophthalmic solution vehicle of OCS-02 Subjects will be randomized to receive vehicle eye drops three times daily (TID) for 6 weeks.

  • Artificial tearsOther

    Subjects who quality after an initial screening were entered into a run-in phase where they received artificial tears to use three times daily (TID) for approximately 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of licaminlimab in subjects with signs of dry eye diseaseTime frame: Baseline to Day 43

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Oculis Investigative Site

    Newport Beach, California

  • Oculis Investigative Site

    Colorado Springs, Colorado

  • Oculis Investigative Site

    Shelby, North Carolina

  • Oculis Investigative Site

    Erie, Pennsylvania

  • Oculis Investigative Site

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.